Since PKCδ activates AKT and MAPK signaling pathways downstream of the targets of TKI (Allen-Petersen et al., 2014[1]), an additional inhibitory effect can be expected after simultaneous inhibition of this kinase, as already suggested in glioma cells (Jane et al., 2006[17]). This evidence concerns the gene AKT1 and central nervous system cancer.